Works by Voorhees, Peter M.

Results: 46
    1
    2
    3
    4
    5

    Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium.

    Published in:
    Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-00993-0
    By:
    • Afrough, Aimaz;
    • Hashmi, Hamza;
    • Hansen, Doris K.;
    • Sidana, Surbhi;
    • Ahn, Chul;
    • Peres, Lauren C.;
    • Dima, Danai;
    • Freeman, Ciara L.;
    • Puglianini, Omar Castaneda;
    • Kocoglu, Mehmet H.;
    • Atrash, Shebli;
    • Voorhees, Peter M.;
    • Shune, Leyla;
    • McGuirk, Joseph P.;
    • Simmons, Gary;
    • Sborov, Douglas W.;
    • Davis, James A.;
    • Kaur, Gurbakhash;
    • Sannareddy, Aishwarya;
    • Ferreri, Christopher J.
    Publication type:
    Article
    6

    Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy.

    Published in:
    Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00886-8
    By:
    • Ferreri, Christopher J.;
    • Hildebrandt, Michelle A. T.;
    • Hashmi, Hamza;
    • Shune, Leyla O.;
    • McGuirk, Joseph P.;
    • Sborov, Douglas W.;
    • Wagner, Charlotte B.;
    • Kocoglu, M. Hakan;
    • Rapoport, Aaron;
    • Atrash, Shebli;
    • Voorhees, Peter M.;
    • Khouri, Jack;
    • Dima, Danai;
    • Afrough, Aimaz;
    • Kaur, Gurbakhash;
    • Anderson Jr., Larry D.;
    • Simmons, Gary;
    • Davis, James A.;
    • Kalariya, Nilesh;
    • Peres, Lauren C.
    Publication type:
    Article
    7

    Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study.

    Published in:
    Blood Cancer Journal, 2020, v. 10, n. 10, p. 1, doi. 10.1038/s41408-020-00369-0
    By:
    • Richardson, Paul G.;
    • Lee, Hans C.;
    • Abdallah, Al-Ola;
    • Cohen, Adam D.;
    • Kapoor, Prashant;
    • Voorhees, Peter M.;
    • Hoos, Axel;
    • Wang, Karrie;
    • Baron, January;
    • Piontek, Trisha;
    • Byrne, Julie;
    • Richmond, Scott;
    • Jewell, Roxanne C.;
    • Opalinska, Joanna;
    • Gupta, Ira;
    • Lonial, Sagar
    Publication type:
    Article
    8

    Oprozomib in patients with newly diagnosed multiple myeloma.

    Published in:
    Blood Cancer Journal, 2019, v. 9, n. 9, p. N.PAG, doi. 10.1038/s41408-019-0232-6
    By:
    • Hari, Parameswaran;
    • Matous, Jeffrey V.;
    • Voorhees, Peter M.;
    • Shain, Kenneth H.;
    • Obreja, Mihaela;
    • Frye, John;
    • Fujii, Hisaki;
    • Jakubowiak, Andrzej J.;
    • Rossi, Davide;
    • Sonneveld, Pieter
    Publication type:
    Article
    9
    10
    11
    12
    13
    14
    15
    16

    Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma.

    Published in:
    Cancer (0008543X), 2024, v. 130, n. 15, p. 2629, doi. 10.1002/cncr.35319
    By:
    • Suvannasankha, Attaya;
    • Bahlis, Nizar;
    • Trudel, Suzanne;
    • Weisel, Katja;
    • Koenecke, Christian;
    • Oriol, Albert;
    • Voorhees, Peter M.;
    • Alonso, Aranzazu A.;
    • Callander, Natalie S.;
    • Mateos, María‐Victoria;
    • Reddy, Nishitha;
    • Hakim, Shawn;
    • LaMacchia, John;
    • Patel, Nashita;
    • Williams, Danaé;
    • Jewell, Roxanne C.;
    • Zhou, Xiangdong;
    • Gupta, Ira;
    • Opalinska, Joanna;
    • Nooka, Ajay K.
    Publication type:
    Article
    17

    A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma.

    Published in:
    British Journal of Haematology, 2013, v. 161, n. 3, p. 357, doi. 10.1111/bjh.12266
    By:
    • Voorhees, Peter M.;
    • Manges, Robert F.;
    • Sonneveld, Pieter;
    • Jagannath, Sundar;
    • Somlo, George;
    • Krishnan, Amrita;
    • Lentzsch, Suzanne;
    • Frank, Richard C.;
    • Zweegman, Sonja;
    • Wijermans, Pierre W.;
    • Orlowski, Robert Z.;
    • Kranenburg, Britte;
    • Hall, Brett;
    • Casneuf, Tineke;
    • Qin, Xiang;
    • Velde, Helgi;
    • Xie, Hong;
    • Thomas, Sheeba K.
    Publication type:
    Article
    18
    19
    20
    21
    22

    Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal DREAMM‐2 study.

    Published in:
    Cancer (0008543X), 2021, v. 127, n. 22, p. 4198, doi. 10.1002/cncr.33809
    By:
    • Lonial, Sagar;
    • Lee, Hans C.;
    • Badros, Ashraf;
    • Trudel, Suzanne;
    • Nooka, Ajay K.;
    • Chari, Ajai;
    • Abdallah, Al‐Ola;
    • Callander, Natalie;
    • Sborov, Douglas;
    • Suvannasankha, Attaya;
    • Weisel, Katja;
    • Voorhees, Peter M.;
    • Womersley, Lynsey;
    • Baron, January;
    • Piontek, Trisha;
    • Lewis, Eric;
    • Opalinska, Joanna;
    • Gupta, Ira;
    • Cohen, Adam D.
    Publication type:
    Article
    23
    24

    Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study.

    Published in:
    British Journal of Haematology, 2024, v. 204, n. 6, p. 2227, doi. 10.1111/bjh.19386
    By:
    • Nooka, Ajay K.;
    • Kaufman, Jonathan L.;
    • Rodriguez, Cesar;
    • Jakubowiak, Andrzej;
    • Efebera, Yvonne;
    • Reeves, Brandi;
    • Wildes, Tanya M.;
    • Holstein, Sarah A.;
    • Anderson, Larry D.;
    • Badros, Ashraf;
    • Shune, Leyla;
    • Chari, Ajai;
    • Pei, Huiling;
    • Cortoos, Annelore;
    • Patel, Sharmila;
    • Lin, Thomas S.;
    • Voorhees, Peter M.;
    • Usmani, Saad Z.;
    • Richardson, Paul G.
    Publication type:
    Article
    25

    Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study.

    Published in:
    British Journal of Haematology, 2022, v. 199, n. 3, p. 355, doi. 10.1111/bjh.18432
    By:
    • Sborov, Douglas W.;
    • Baljevic, Muhamed;
    • Reeves, Brandi;
    • Laubach, Jacob;
    • Efebera, Yvonne A.;
    • Rodriguez, Cesar;
    • Costa, Luciano J.;
    • Chari, Ajai;
    • Silbermann, Rebecca;
    • Holstein, Sarah A.;
    • Anderson, Larry D.;
    • Kaufman, Jonathan L.;
    • Shah, Nina;
    • Pei, Huiling;
    • Patel, Sharmila;
    • Cortoos, Annelore;
    • Bartlett, J. Blake;
    • Vermeulen, Jessica;
    • Lin, Thomas S.;
    • Voorhees, Peter M.
    Publication type:
    Article
    26
    27
    28
    29
    30
    31

    A Clinical and Correlative Study of Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd) for Lenalidomide Refractory Multiple Myeloma in First Relapse.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 7, p. 535, doi. 10.1016/j.clml.2023.03.016
    By:
    • Bhutani, Manisha;
    • Foureau, David M.;
    • Robinson, Myra;
    • Guo, Fei;
    • Fesenkova, Kateryna;
    • Atrash, Shebli;
    • Paul, Barry;
    • Varga, Cindy;
    • Friend, Reed;
    • Pineda-Roman, Mauricio;
    • Rigby, Katherine;
    • Symanowski, James T.;
    • Norek, Sarah;
    • Tucker, Mallory R.;
    • Druhan, Lawrence J.;
    • Voorhees, Peter M.;
    • Usmani, Saad Z.
    Publication type:
    Article
    32
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42

    Bone marrow Ki‐67 index is of prognostic value in newly diagnosed multiple myeloma.

    Published in:
    European Journal of Haematology, 2023, v. 111, n. 3, p. 373, doi. 10.1111/ejh.14016
    By:
    • Atrash, Shebli;
    • Robinson, Myra;
    • Taneja, Alankrita;
    • Paul, Barry;
    • Cassetta, Kristen;
    • Ndiaye, Ami;
    • Varga, Cindy;
    • Block, Jared;
    • Lipford, Edward H.;
    • Smith, Elton T.;
    • McCall, Chad M.;
    • Thurston, Virginia;
    • Foureau, David;
    • Usmani, Saad Z.;
    • Voorhees, Peter M.;
    • Bhutani, Manisha
    Publication type:
    Article
    43
    44
    45
    46